Methylene Blue has a potent antiviral activity against SARS-CoV-2 and H1N1 influenza virus in the absence of UV-activation in vitro
| Autor: | Caroline Tapparel, Thomas Cerny, Chiara Medaglia, Andreas Cerny, Erich H Cerny, Valeria Cagno, Arnaud Charles-Antoine Zwygart |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Drug Ultraviolet Rays Science media_common.quotation_subject viruses Pharmacology Virus Replication Methemoglobinemia Article Virus 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Chlorocebus aethiops Influenza Human medicine Animals Humans 030212 general & internal medicine Vero Cells Incubation media_common ddc:616 COVID-19/drug therapy COVID-19/genetics COVID-19/virology Influenza Human/drug therapy Influenza Human/genetics Influenza Human/virology Methylene Blue/pharmacology SARS-CoV-2/drug effects SARS-CoV-2/pathogenicity Ultraviolet Rays/adverse effects Virus Inactivation/drug effects Virus Inactivation/radiation effects Virus Replication/drug effects Virus Replication/radiation effects Multidisciplinary SARS-CoV-2 Chemistry COVID-19 virus diseases medicine.disease In vitro COVID-19 Drug Treatment Methylene Blue Antiviral agents 030104 developmental biology Viral replication Viral infection Vero cell Virus Inactivation Medicine Methylene blue |
| Zdroj: | Scientific Reports, Vol. 11, No 1 (2021) P. 14295 Scientific reports, vol. 11, no. 1, pp. 14295 Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Methylene blue is an FDA (Food and Drug Administration) and EMA (European Medicines Agency) approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. In this study, we first evaluated the virucidal activity of methylene blue against influenza virus H1N1 upon different incubation times and in the presence or absence of light activation, and then against SARS-CoV-2. We further assessed the therapeutic activity of methylene blue by administering it to cells previously infected with SARS-CoV-2. Finally, we examined the effect of co-administration of the drug together with immune serum. Our findings reveal that methylene blue displays virucidal preventive or therapeutic activity against influenza virus H1N1 and SARS-CoV-2 at low micromolar concentrations and in the absence of UV-activation. We also confirm that MB antiviral activity is based on several mechanisms of action as the extent of genomic RNA degradation is higher in presence of light and after long exposure. Our work supports the interest of testing methylene blue in clinical studies to confirm a preventive and/or therapeutic efficacy against both influenza virus H1N1 and SARS-CoV-2 infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|